Prevention of injury by resveratrol in a rat model of adenine-induced chronic kidney disease

Xiaoyan Zhang,Zhenning Yang,Yanhong Qiao,Leifang Li,Haiyan Jiao,Congxiu Miao

doi:10.4314/tjpr.v16i8.37

Xiaoyan Zhang, Zhenning Yang + Show 4 more

Open Access

https://doi.org/10.4314/tjpr.v16i8.37

Copy DOI

Abstract

Purpose: To investigate the preventive effect of resveratrol against renal pathological changes in a rat model of chronic kidney disease (CKD). Methods: CKD was induced by daily intragastric administration of adenine (200 mg/kg) for 1 month. The effect of 10, 15, and 20 mg/kg doses of resveratrol on the levels of parathyroid hormone, phosphorous, and fibroblast growth factor-23 (FGF-23) in rat urine samples after 2 months of adenine administration were analyzed using an auto-analyzer. Results: Resveratrol treatment significantly inhibited the adenine-mediated increase in serum parathyroid hormone, phosphorous and FGF-23 levels ( p < 0.002). In rats treated with 10, 15 and 20 mg/kg doses of resveratrol after adenine, urine protein/creatinine ratio was reduced to 5, 675.6 ± 2453.7, 4, 789.8 ± 1,534.9, and 1, 965 ± 576.8 mg/g, respectively. In the untreated and normal control groups, the respective values were 7, 004 ± 1, 653.3 and 1, 627.5 ± 568.7 mg/g. Treatment with resveratrol after administration of adenine inhibited increases in creatinine, blood urea nitrogen, and uric acid levels in a dose-dependent manner ( p < 0.002). Resveratrol treatment also inhibited adeninemediated increases in monocytes and inflammatory cells. Furthermore, resveratrol prevented renal tubule swelling and expansion induced by adenine administration. Conclusion: Resveratrol treatment prevent the renal pathological changes induced by adenine administration in a rat model of CKD by inhibiting FGF-23, parathyroid hormone, and phosphate. Thus, resveratrol may be of therapeutic importance for the treatment of CKD. Keyword: Parathyroid hormone, Phosphate, Creatinine, Monocytes, Chronic kidney disease, Fibroblast growth factor-23

Highlights

Chronic kidney disease (CKD) is associated with inflammation and hemodynamic changes that result in scarring of the renal tubules and interstitial spaces, and the development of end-stage renal disease [1]
Studies have shown that a prolonged increase in the serum levels of proteinuria and fibroblast growth factor-23 (FGF-23) is the main cause of end-stage renal disease [2,3]
This study examined the utility of resveratrol for treating CKD by suppressing the expression of inorganic phosphate, parathyroid hormone, and FGF-23 in a rat model

Summary

INTRODUCTION

Chronic kidney disease (CKD) is associated with inflammation and hemodynamic changes that result in scarring of the renal tubules and interstitial spaces, and the development of end-stage renal disease [1]. High levels of inorganic phosphate, parathyroid hormone, and FGF-23 in the serum promote the development of CKD [5]. Another factor that contributes to the development of kidney and heart disease is the presence of high levels of protein in urine [6]. Resveratrol treatment inhibits the production of inducible nitric oxide synthase by human epithelial cells [10]. It prevents cartilage degradation in animal models of arthritis [11]. This study examined the utility of resveratrol for treating CKD by suppressing the expression of inorganic phosphate, parathyroid hormone, and FGF-23 in a rat model

METHODS

RESULTS

DISCUSSION

Findings

Conflict of Interest